57 Outcomes in Surgically Resected T3N0 NSCLC in the Dutch population Table 3. Three-year overall survival (OS) with 95% CIs for the pT3 categories and other clinicopathological characteristics. (continued) Characteristic 3-yr OS 95% CI p-value HR 95% CI p-value 5-yr OS Resection side 0.38 n.i. Right 58.1% 53.2% - 63.1% Left 55.4% 49.5% - 61.3% Chemotherapy <0.001 <0.001 No 50.4% 45.5% - 55.3% 1.0 Yes 67.5% 61.7% - 73.2% 0.6 0.45 - 0.74 Radiotherapy 0.04 n.s. No 58.3% 54.3% - 62.3% Yes 45.9% 34.0% - 57.7% Chemo and/or radiation <0.001 n.i. None 52.3% 47.1% - 57.5% Only CT 67.8% 61.8% - 73.9% Only RT 33.7% 19.1% - 48.2% Both 63.9% 45.8% - 82.0% Note: the four major subtypes are as follows: larger than 7 cm, second or multiple nodules in the same lobe, pleural invasion and mixed HR, Hazard Ratio; n.s., not significant; n.i., not included in model selection; AdC, adenocarcinoma; SqCC, squamous cell carcinoma; NSCLC-NOS, non-small cell lung cancer, not otherwise specified; CT, chemotherapy; RT, radiotherapy; Rx, microscopic resection margin unknown; R0, microscopic negative resection margin; R1, microscopic positive resection margin. Within the group with subtype two or more nodules, patients with adenocarcinoma had a better prognosis than did those with squamous cell carcinoma with 5 years OS of 65.1% vs 47.2% (p=0.004), respectively, whereas the differences were not significant for the other three subtypes (tumor diameter larger than 7 cm’ [p=1.00], pleural invasion [p=0.47], and mixed [p=0.76]), (Fig. 4 and Table 4). 4
RkJQdWJsaXNoZXIy MTk4NDMw